Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Efficacy of KPI-121 1.0% Ophthalmic Suspension in Subjects With Postsurgical Inflammation and Pain

NCT02793817 is registered in ClinicalTrials.gov with Kala Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02793817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02793817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Efficacy of KPI-121 1.0% Ophthalmic Suspension in Subjects With Postsurgical Inflammation and Pain
Lead sponsor
Kala Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2016
Completion date
March 31, 2017
Enrollment
520 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

post surgical ocular inflammation and pain